Citius Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Citius Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Citius Pharmaceuticals Inc recorded a cumulative net loss of $-59 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -43.81%.

However, within the Healthcare sector 523 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3831, from total ROA ranking in the second quarter of 2026 at 4253.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter
Y / Y Total Assets Change	11.42 %	3.81 %	396.49 %	396.49 %	31.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-59	-56	-37	-38	-40
Return On Assets (TTM)	-43.81 %	-42.96 %	-28.74 %	-36.88 %	-52.2 %
CTXR's Total Ranking	# 3831	# 4253	# 3772	# 3834	# 3964
Total Assets (TTM) in million	142	133	131	131	128
Seq. Total Assets Change	7.33 %	1.22 %	0 %	2.55 %	0 %
Seq. Net Income Change	-	-	-	-	-

CTXR's 5 Years Annual ROA >> Back to CTXR Management Effectiveness >> Compare CTXR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 216
Sector	# 524
Overall	# 3812

Return On Assets Statistics
High	Average	Low
-17.05 %	-1274.02 %	-22752.29 %
(Dec 31 2021)		(Jun 30 2013)

Financial Statements
Citius Pharmaceuticals Inc 's Assets	$ 142 million	CTXR's Balance sheet
Citius Pharmaceuticals Inc 's Income	$ -12 million	Quarterly CTXR's Income Statement
CTXR's Income by Division		See CTXR's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021
Y / Y Total Assets Change	396.49 %	-74.55 %	-9.08 %	-19.99 %	228.27 %
Total Assets in million	131	26	104	114	142
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-40	-39	-34	-34	-23
Annual Return On Assets	-30.35 %	-149.5 %	-32.52 %	-29.52 %	-16.19 %

CTXR's 5 Years Annual ROA >> Back to CTXR Management Effectiveness >> Compare CTXR ROA to its Competitors

More Return On Assets Ratios
CTXR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CTXR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CTXR's Competitors
Subscribers only: Roa for Citius Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for CTXR's Customers

You may also want to know
CTXR's Roi	CTXR's Inventory Turnover Ratio	CTXR's Growth Rates	CTXR's Dividend Comparisons
	CTXR's Profitability Ratios	CTXR's Asset Turnover Ratio	CTXR's Dividend Growth
CTXR's Roe	CTXR's Valuation Ratios	CTXR's Financial Strength Ratios	CTXR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:21:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.